PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.
Sabrina MarcazzanMarcos J Braz CarvalhoNghia T NguyenJulia StrangmannJulia Slotta-HuspeninaAnna TenditnayaMarkus TschurtschenthalerJonas RiederAndrea Proaño-VascoVasilis NtziachristosKatja SteigerDimitris GorpasMichael QuanteSusanne KossatzPublished in: Journal of experimental & clinical cancer research : CR (2024)
PARPi-FL imaging is a promising approach for clinically needed improved detection of dysplastic and malignant EAC lesions in patients with BE. Since PARPi-FL is currently evaluated in a phase 2 clinical trial for oral cancer detection after topical application, clinical translation for early detection of dysplasia and EAC in BE patients via FME screening appears feasible.
Keyphrases
- clinical trial
- end stage renal disease
- ejection fraction
- loop mediated isothermal amplification
- chronic kidney disease
- high resolution
- dna damage
- single molecule
- prognostic factors
- real time pcr
- dna repair
- randomized controlled trial
- open label
- patient reported outcomes
- radiation therapy
- photodynamic therapy
- sensitive detection
- phase iii